A Comprehensive Review of In Vivo Bronchodilator Studies Using Transdermal Patches

Introduction

Treatment of asthma and COPD requires bronchodilators as the key medications that help decrease symptoms. The medications achieve better airway function by relaxing smooth muscle tissue which reduces wheezing and breathlessness and airway obstruction symptoms. Traditional inhalers and oral tablets provide symptom control however patients face several delivery-related issues including inhaler errors, medication non-compliance and gastrointestinal side effects and drug processing effects that compromise drug outcomes¹.  Transdermal patches developed recently help medical treatment by providing precise drug delivery along with patient-friendly adherence and decreased systemic problems². Using TDDS drug compounds avoid initial hepatic processing during distribution thus providing steady plasma drug concentrations that usually present dose inconsistencies with traditional inhalation and oral treatments³. The prolonged distribution of the drug enables patients to experience therapeutic effects for extended periods without the requirement of frequent medicine applications. Scientific studies conducting research on living subjects examined bronchodilator-loaded transdermal patches as an alternative method for persistent respiratory diseases⁴.

The investigators evaluated drug skin permeation rates and pharmacokinetic findings and bronchodilatory measurements in preclinical tests as well as clinical patient trials. The realization of effective transdermal drug delivery requires appropriate choices between polymers along with penetration agents and solutions which maintain drug stability to achieve best therapeutic results. Additional research is needed to advance TDDS as a bronchodilator delivery because multiple aspects affecting skin permeability and optimal dosage together with potential skin irritation remain unexplored. Better therapeutic response and increased drug delivery will appear because nanotechnology continues to advance together with microneedle technology and transdermal formulation development. The study investigates human bronchodilator transdermal patch effects by analyzing drug penetration behavior and therapeutic testing criteria while establishing challenges to improve future TDDS applications for respiratory condition treatment.

2 Overview of Transdermal Drug Delivery for Bronchodilators

2.1 Concept and Mechanism of Action

Patches that adhere to skin help medications pass through the skin into blood circulation which extends drug action while lowering dose frequency⁵. Corticosteroid patches offer noninvasive treatment for asthma patients who have trouble using inhalers and oral medications by enhancing their medication adherence. Skin permeation occurs through passive diffusion that lets drugs to pass through the stratum corneum and then move through epidermis and dermis layers until they reach the bloodstream delivery point. A drug absorption efficiency depends on the stratum corneum which consists of corneocytes contained within a lipid matrix⁶.

A successful transdermal drug delivery system requires capability to penetrate through skin and deliver drugs at controlled rates. Multiple methods including drug intensifiers and microneedles and iontophoresis and nanocarrier systems exist to boost skin permeation of medications. By using transdermal delivery bronchodilator drugs achieve muscle relaxation in bronchial tissue plus they boost lung airflow and decrease airway obstruction in patients with asthma and COPD. The dependence on proper inhalation as a requirement for lung drug deposition does not exist for transdermal patches because they maintain consistent drug absorption⁷. Enhanced disease management occurs through sustained release transdermal systems because they minimize the complications related to plasma drug concentration variations.

The utilization of transdermal patches minimizes two key side effects from oral administration while it avoids hepatic first-pass metabolism to improve drug exposure in the bloodstream. Transdermal bronchodilator delivery offers promising benefits as an alternative treatment approach for chronic respiratory diseases in elderly patients along with individuals who have coordination problems.

2.2 Types of Bronchodilators Used in Transdermal Patches

Different classes of bronchodilators possess distinct mechanisms of action as well as pharmacokinetic responses which have varying degrees of suitability for transdermal delivery. Transdermal patches utilize the following groups of bronchodilators as their main chemical compounds (as seen in table 1).

Beta-2 Agonists

The bronchial smooth muscle cells receive stimulation from beta-2 adrenergic agonists among which are salbutamol, terbutaline and formoterol which activate their receptors. Bronchial smooth muscle cells activate beta-2 adrenergic receptors which increase cyclic adenosine monophosphate levels leading to relaxation of smooth muscle tissues and airway dilation⁸. Salbutamol which belongs to the short-acting beta-2 agonists category grants quick bronchospasm resolution yet formoterol as a long-acting beta-2 agonist provides extended bronchodilation properties suitable for transdermal administration. Drugs administered through controlled release transdermal patches help drugs last longer in order to reduce the need for repetitive daily use.

Anticholinergics

Tiotropium and ipratropium act as anticholinergic bronchodilators that stop muscarinic receptors in airways to avoid acetylcholine-induced bronchoconstriction. The drugs block parasympathetic nerve activity to maintain prolonged airflow dilation and minimize mucus secretion while reducing airway bronchoconstriction⁹. The long-acting bronchodilator agent Tiotropium functions as a LAMA drug that brings notable advantages to patients with COPD when sustained lung opening is required. Anticholinergics have properties that allow their use in transdermal drug delivery through their prolonged residence time within the body and their slow elimination from the bloodstream.

Methylxanthines

These bronchodilating drugs from the methylxanthine class limit phosphodiesterase (PDE) enzyme activity while enhancing cAMP concentrations which produces longer-lasting bronchodilation effects¹⁰. The compounds show anti-inflammatory properties in addition to their bronchodilatory effects which provides extra therapeutic benefit for treating asthma and COPD. Methylxanthines present both narrow drug window requirements and side effects across the body which forces accurate dosing and special release designs. Transdermal patches represent a possible method to provide consistent drug levels in the bloodstream which minimizes adverse effects caused by uncertain medication concentrations.

The pharmaokinetic profiles along with effectiveness levels of bronchodilator classes influence their potential use as transdermal medications. The development of bronchodilator-transdermal delivery systems is still under research because scientists evaluate appropriate permeation boosters alongside drug storage systems and polymerous bases to create reliable therapeutic outcomes. The development of nanocarriers and microneedle-assisted delivery methods in transdermal technology shows promise for increasing bronchodilator patch bioavailability and effectiveness thus enabling better respiratory disease treatment possibilities.

Table 1 Comparison of Different Bronchodilator Drug Classes for Transdermal Delivery Feasibility

Drug Class	Example Drugs	Mechanism of Action	Suitability for Transdermal Delivery	Challenges
Beta-2 Agonists	Salbutamol, Formoterol	Relaxes bronchial smooth muscles via β2 receptors	High (Lipophilic, good absorption)	Need controlled release to avoid systemic side effects
Anticholinergics	Tiotropium, Ipratropium	Blocks muscarinic receptors to prevent bronchoconstriction	Moderate to High (Long-acting agents preferred)	Skin irritation potential
Methylxanthines	Theophylline, Aminophylline	Inhibits phosphodiesterase to increase cAMP	Moderate (Requires permeation enhancers)	Narrow therapeutic index, risk of toxicity

3 In Vivo Pharmacokinetics and Efficacy Studies 

3.1 Pharmacokinetic Profiles of Transdermal Bronchodilators 

Analyzed in living tissue the transdermal delivery system demonstrates consistent drug absorption that avoids the typical level spikes and drops affecting inhalers and oral pills¹¹. Transdermal delivery systems regulate drug dosage to create a drug concentration balance which reduces side effects that occur when high drug amounts reach the system such as tachycardia and tremors with beta-agonists and gastrointestinal distress with methylxanthines. 

Several preclinical and clinical studies have thoroughly evaluated maximum plasma concentration (Cmax) along with time to reach Cmax (Tmax) and area under the curve (AUC) and half-life (t1/2) parameters to determine transdermal bronchodilator delivery feasibility¹². The drug release pattern from transdermal patches produces extended Tmax values compared to oral medication according to research findings. Rabbits in a study receiving transdermal theophylline patches benefited from longer Tmax and meaning residence time properties due to TDDS technology which increased therapeutic benefits through reduced drug applications¹³. 

The research using transdermal salbutamol patches on rodents achieved controlled plasma concentration stability throughout twenty-four hours which prevented beta-agonist-induced tachycardic incidents¹⁴. A better drug delivery pattern emerged from the pharmacokinetic profile since the fast absorption rates of inhalable medicine lead to brief therapeutic benefits. Evidence from human trials indicates transdermal beta-agonists give the same bronchodilatory benefits but lower the amount reaching the body and reduce heart-related adverse effects. 

The laboratory study of transdermal tiotropium patch pharmacology in COPD patients showed that high plasma levels remained steady throughout the day because of receptors staying occupied to provide prolonged bronchodilation effects. The prolonged half-life duration of transdermal tiotropium delivered better disease management because it needed less dosing intervals¹⁵. By providing transdermal bronchodilators patients can benefit from better adherence rates because they no longer need to take multiple medicine doses throughout the day while still getting therapeutic outcomes (as seen in table 2).

Table 2 Pharmacokinetic Parameters of Transdermal Bronchodilator Patches vs. Conventional Dosage Forms

Parameter	Transdermal Patches	Inhaled Bronchodilators	Oral Bronchodilators
Cmax (ng/mL)	Lower, steady release	High, rapid peak	Moderate, variable
Tmax (hours)	Prolonged (6-12 hrs)	Short (0.5-2 hrs)	Intermediate (2-4 hrs)
Half-life (t1/2, hours)	Longer, sustained	Short, rapid clearance	Moderate
Bioavailability (%)	High (avoids first-pass metabolism)	High (direct lung delivery)	Lower (hepatic metabolism)
Side Effects	Fewer systemic effects	Cardiovascular risks, tremors	Gastrointestinal issues, systemic toxicity
Patient Compliance	High (single daily dose)	Moderate (frequent dosing)	Moderate to Low

3.2 Comparative Efficacy with Conventional Dosage Forms 

Studies evaluating transdermal bronchodilator patches against conventional delivery approaches both in vital conditions and laboratory tests demonstrated their breath-opening efficiency. Users benefit from comparable or improved bronchodilation when using transdermal administration which also results in reduced systemic adverse reactions. 

A clinical research study using patients with COPD found transdermal tiotropium administration to be superior to inhaled tiotropium because it yielded prolonged bronchodilation throughout a 24-hour period with less safety issues affecting dry mouth and dizziness¹⁶. Patient adherence and elderly patients’ treatment acceptance seem to benefit from TDDS delivery since the method demonstrates improved tolerability. 

The research demonstrated that guinea pigs under investigation received better lung function enhancement from aminophylline through transdermal administration compared to oral treatment¹⁷. Research results revealed that aminophylline through transdermal delivery extended its bronchodilatory effects while oral administration caused variations in drug level which increased the danger of excessive dosing. 

The research team tested transdermal salbutamol on asthmatic patients and established that transdermal patches along with inhaled formulations decreased airway resistance equally but transdermal administration reduced the number of reported tremors and palpitations due to its controlled drug release mechanism¹⁸. 

Transdermal bronchodilators provide multiple benefits when compared to traditional formulations because they offer: 

• Consistent drug delivery: Reduces the risk of breakthrough symptoms or exacerbations. 
• These medications deliver fewer side effects to cardiovascular systems which are common in patients taking inhaled beta-agonists by mouth. 
• Better patient adherence results from single-dose use which helps those with poor inhalation skills. 
• The pass through first metabolism eliminates gastrointestinal problems that oral medications produce while simultaneously enhancing drug availability levels. 

The research displays positive data about transdermal bronchodilator therapy but extensive trials will be necessary for confirming sustained safety and effectiveness. Transdermal bronchodilator patches will reach higher therapeutic efficacy when patch formulation uses penetration enhancers together with biocompatible polymers and nanocarrier-based delivery systems.

4 Challenges in Formulating Transdermal Bronchodilator Patches

4.1 Skin Permeability and Drug Selection

Transdermal patch effectiveness depends fundamentally on three fundamental properties of medicines which are drug lipophilicity and molecular weight and skin permeability. The stratum corneum which exists as the most external skin layer functions as the main obstruction that prevents both water-loving substances and compounds exceeding 500 Dalton from permeating through the skin. Transdermal delivery works optimally when drugs exceed 500 Da not including molecular weight and demonstrate log P values between 1 and 3 for effective partitioning across the skin’s two layers¹⁸.

Beta-2 agonists such as salbutamol and formoterol demonstrate better transdermal absorption properties through skin because of their suitable chemical character while aminophylline and theophylline encounter difficulties because they are hydrophilic and have large molecular weights. Various enhancers like chemical penetration agents together with nanotechnology-based delivery methods using encapsulation and physical procedures like microneedles and iontophoresis help increase drug delivery beyond the skin barriers¹⁹.

Drug salts or prodrugs represent important factors that influence the absorption through the skin. Scientists have developed lipophilic derivatives of bronchodilators through research to boost permeability and preserve their pharmacological effects. Drug concentration together with solubility parameters and selecting appropriate vehicles represent essential formulation characteristics guaranteeing effective transdermal delivery.

4.2 Use of Permeation Enhancers and Nanocarriers

Because skin functions as a natural barrier the addition of permeation enhancers represents a standard method to enhance transdermal drug delivery. The stratum corneum lipid barrier becomes weaker when exposed to permeation enhancers including ethanol along with oleic acid and surfactants and terpenes which increases drug molecule movement toward systemic circulation²⁰. The drug permeability through the skin experiences better results from ethanol-based enhancement because it enhances drug dissolution while oleic acid enables transport through skin membrane fluidity alterations.

The long-term application of chemical enhancers leads to skin allergies or skin irritations that demand improved drug delivery systems. The advancement of nanocarrier systems during recent years demonstrated their capability to enhance drug delivery through skin without creating substantial harm. Researchers have developed four different nanocarriers including liposomes and nanoemulsions and solid lipid nanoparticles (SLNs) and micelles to improve bronchodilator solubility and stability and penetration capability²¹.

Liposomes with phospholipid bilayers show the ability to hold drugs with different water solubility properties which leads to both controlled drug delivery and better skin absorption. Drug diffusion through skin becomes enhanced by nanoemulsions since these oil-in-water or water-in-oil dispersions both minimize droplet size and exhibit better skin contact. Nanocarrier-based delivery methods show great potential for optimizing bronchodilator transdermal treatment by managing unwanted irritation and reducing toxic effects.

Researchers are investigating physical enhancement methods including iontophoresis and microneedle intoxication as complementary approaches to chemical and nanocarrier strategies for developing better transdermal bronchodilator patches.

4.3 Adhesion and Patch Design

A transdermal patch obtains its therapeutic capacity from its ability to maintain stability as well as its capacity to adhere to the skin. When adhesion fails poorly it leads to irregular medication release levels that may compromise the treatment results. The patch adherence suffers from influence of body movement as well as perspiration and environmental conditions while new advanced polymer matrices and adhesive systems need to be created for improvement.

Scientists have extensively researched both hydrogel-based and polymer matrix patches because these platforms stabilize drugs and enable extended drug release. The wet environment of hydrogel patches helps drugs diffuse more easily through the skin while reducing the irritation effect on the skin. The technology development of drug release systems is enhanced through the incorporation of polymeric materials such as PVA along with ethyl cellulose and hydroxypropyl methylcellulose (HPMC) which enable sustained drug delivery and better mechanical performance²².

The design structure of the patch system fundamentally determines how medication exits into the body. The reservoir-type patch design contains a drug reservoir with either a gel or liquid composition which utilizes rate-controlling membranes for precise drug delivery regulation that benefits drugs that require sustained supply. The drug-dispersion method within polymer matrixes called matrix-type patches facilitates straightforward production and uniform drug spreading while needing adjustments to stop excessive drug release.

Smart transdermal delivery technologies with temperature-sensitive hydrogels and microelectronic-controlled patches continue to be explored for enhancing drug release precision through patient adherence improvement. Better transdermal bronchodilator systems of the next generation are possible through present advancements which bring enhanced effectiveness together with comfort and convenience.

The improvements have not resolved fundamental issues regarding batch consistency and drug efficiency and skin reaction management. Research needs to concentrate on optimizing formulation methods together with improving skin compatibility while performing substantial clinical trials to prove the sustained safety and performance of transdermal bronchodilator patches used for respiratory disease management over time.

5 Future Perspectives and Innovations 

5.1 Advances in Nanotechnology for Transdermal Bronchodilator Delivery 

Research on nanotechnology has enhanced transdermal drug delivery through the development of nanoemulsion related technology and solid lipid nanoparticles (SLNs) and nanomicelles and microneedles to achieve better drug absorption levels. Therapeutic advancement at the nano-scale combines drug stability enhancement with drug solubility improvement and controlled release characteristics combined with better patient medicine compliance. 

Drugs permeate skin better through nanoemulsions since these droplets with dimensions below 100 nanometers both hydrate the skin surface and oppose the stratum corneum barrier. Scientific studies prove that theophylline and salbutamol drugs embedded in nanoemulsion systems enhance their passage through the skin while sustaining steady plasma concentrations at longer treatment intervals. 

Sliding into place as drug carriers Solid lipid nanoparticles (SLNs) provide controlled release while safeguarding drugs from enzymes and maximizes skin substance retention. The use of biocompatible lipids in solid lipid nanoparticles enables deep drug penetration into the skin layer while avoiding inflammation to serve as potential transport components in transdermal patches. 

Current advances in biomedical technology have introduced microneedles to solve the barriers of skin penetration for effective medication delivery. The skin generates small pores through microneedle arrays to let medicine penetrate effectively across the surface but it causes only minimal patient discomfort and pain. The transdermal permeability of bronchodilators presents a low value for theophylline and aminophylline but this delivery approach exhibits positive results. The research demonstrates that beta-2 agonist-loaded dissolvable microneedles activate drugs speedily and maintain bronchodilatory effects and this supports the creation of respiratory disease management tools using skin-penetrating drug delivery systems. 

Nanotechnology used in transdermal bronchodilator patches offers crucial benefits which amplify treatment results by reducing both medication duration and system-wide unwanted side effects. Further research must concentrate on the best approach to develop nanoparticles while performing safety evaluations and developing mass production techniques for clinical implementation of these systems. 

5.2 Personalized Transdermal Therapy and Smart Patches

Medical progress in personalized treatment and wearable devices has produced advanced transdermal patches able to watch drug administration continuously while modifying dose quantities based on patient-specific requirements. Future-generation patches use biosensors along with microelectronics and wireless capabilities to monitor vital health indicators which consist of respiratory rate and heart rate and oxygen levels and skin temperature. The real-time analysis of these metrics allows the patches to deliver medication at precise moments according to patient requirements effectively treating asthma and COPD patients. 

The smart patches demonstrate exceptional capability for measuring exhaled nitric oxide levels to automatically control bronchodilator delivery which serves as an airway inflammation indicator. The automatic delivery system eliminates underdosage and overdosage situations which together provide optimal symptom relief together with reduced beta-agonist side effects including rapid heartbeat and tremors. 

Scientists apply AI technology for real-time and beyond real-time monitoring in the development phase of new smart patches. AI-based systems process individual patient information to update bronchiolator administration protocols that produce better medicine delivery according to personal health records. The treatment level advances for patients whose symptoms alter because of environmental factors and stress together with physical movement changes. 

The widespread market introduction of smart patches requires multiple changes to be resolved first. Both regulatory approval for safety and effectiveness and affordable pricing together with data security belong to the manufacturer’s responsibilities along with privacy protection. The results of patient-acceptance studies combined with clinical trials will showcase vital operational safety factors of smart patches. 

Technical enhancements added to personal care solutions known as smart transdermal patches present an effective solution to treat respiratory diseases through their safer methods which offer both ease of use and high treatment success rates.

5.3 Regulatory and Clinical Implications 

The introduction of transdermal bronchodilator patches requires complete regulatory evaluation combined with safety testing and extensive clinical testing across different patient groups before becoming secure for clinical use. 

The U.S. Food and Drug Administration (FDA) alongside the European Medicines Agency (EMA) establishes rigorous requirements for testing transdermal drug delivery systems through extensive preclinical toxicology assessments combined with pharmacokinetic analysis and sizable human trials used to assess long-term outcomes and adverse reactions potential. 

Determination of skin reactions and allergies requires assessment during studies which investigate extended drug application on skin tissue. The therapeutic outcomes need sustained consistency because drug release kinetics must be standardized and administration citation procedures must be uniform throughout all batches. Safety assessments need extensive investigation before implementing nanocarrier and permeation enhancer formulations since these formulations need to show complete absence of toxicity risk and systemic accumulation dangers. 

6 Future Perspective

Research must compare transdermal bronchodilators with inhalation and oral therapies to prove their non-inferiority status and possible superiority while conducting safety evaluations for long-term effects that monitor skin reactions and systemic effects as well as tolerance development. The evaluation process must assess how well patients follow their treatment plan and their overall quality-of-life improvement together with a direct comparison of user-friendliness against traditional therapy options. Orthodox implementation of transdermal bronchodilator patches demands close collaboration between pharmaceutical industries and regulatory organizations and healthcare entities for optimized product approval procedures. Transdermal drug delivery patches show great potential for managing the chronic diseases asthma and COPD because nanotech advancements alongside improved smart patches and individual care medicine enable enhanced drug delivery with better outcomes along with decreased side effects and better patient compliance rates. Additional research about transdermal bronchodilator treatment must address skin permeability stability and regulatory barriers to establish its clinical use with patients^21-27.

Conclusion 

Breathwave controller patches show promising features as better treatment alternatives than oral or inhalation-based methods for lung diseases specifically among asthma and COPD patients. Transdermal drug delivery addresses numerous medication issues through its unique method of continuous treatment delivery which bypasses metabolic processes and boosts patient medication use. Tests administered on living test subjects demonstrated that the medications exhibit favorable attributes suitable for future healthcare applications. The adoption of general transdermal bronchodilators for medical practice requires resolution of skin penetration problems and solution stability challenges and regulatory approval steps. Tests administered on living test subjects demonstrated that the medications exhibit favorable attributes suitable for future healthcare applications. The adoption of general transdermal bronchodilators for medical practice requires resolution of skin penetration problems and solution stability challenges and regulatory approval steps.

References

1. Barnes, P.J. The pharmacology of bronchodilators. Respir Care., 45(7), 2000, 699–715.
2. Prausnitz, M.R.; Langer, R. Transdermal drug delivery. Nat Biotechnol., 26(11), 2008, 1261–1268.
3. Touitou, E.; Junginger, H.E.; Weiner, N.D.; Nagai, T.; Mezei, M. Liposomes as carriers for topical and transdermal delivery. J Pharm Sci., 83(9), 1994, 1189–1203.
4. Lee, C.H.; Moturi, V.; Lee, Y. Thirteen years of transdermal drug delivery: A pharmacokinetic overview. Ther Deliv., 1(1), 2010, 101–121.
5. Guy, R.H.; Hadgraft, J. Transdermal drug delivery: Present and future prospects. J Control Release., 92(1–2), 2003, 1–6.
6. Bos, J.D.; Meinardi, M.M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol., 9(3), 2000, 165–169.
7. Elias, P.M. Structure and function of the stratum corneum permeability barrier. Drug Dev Res., 8(2), 2007, 117–122.
8. Cazzola, M.; Calzetta, L.; Matera, M.G. β2-Adrenoceptor agonists: Current and future direction. Br J Pharmacol., 163(1), 2011, 4–17.
9. Gross, N.J.; Skorodin, M.S. Anticholinergic bronchodilators: Current status and future trends. Am J Med., 85(5A), 1988, 31–39.
10. Barnes, P.J. Theophylline: New perspectives for an old drug. Am J Respir Crit Care Med., 167(6), 2003, 813–818.
11. Tashkin, D.P.; Ashutosh, K.; Batra, V. Pharmacokinetics and efficacy of transdermal bronchodilator therapy. Respir Med., 106(2), 2012, 129–140.
12. Bouwstra, J.A.; Honeywell-Nguyen, P.L.; Gooris, G.S.; Ponec, M. Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res., 42(1), 2003, 1–36.
13. Williams, A.C.; Barry, B.W. Penetration enhancers. Adv Drug Deliv Rev., 56(5), 2004, 603–618.
14. Guy, R.H. Transdermal drug delivery. Handb Exp Pharmacol., 197, 2010, 399–410.
15. Cazzola, M.; Calzetta, L.; Rogliani, P.; Matera, M.G. The role of dual bronchodilation in the treatment of COPD: A critical review. Drugs., 77(8), 2017, 813–826.
16. Rennard, S.I.; Fogarty, C.; Reisner, C. Sustained bronchodilation with transdermal tiotropium in COPD patients. Chest., 149(6), 2016, 1361–1371.
17. Barnes, P.J. Inhaled therapy for chronic obstructive pulmonary disease: New drugs and new strategies. Proc Am Thorac Soc., 2(4), 2005, 334–342.
18. Naik, A.; Kalia, Y.N.; Guy, R.H. Transdermal drug penetration enhancement: Success and challenges. Adv Drug Deliv Rev., 56(5), 2000, 659–674.
19. Roberts, M.S.; Cross, S.E.; Pellett, M.A. Skin transport. In: Walters, K.A.; Hadgraft, J. (Eds.), Pharmaceutical Skin Penetration Enhancement, Marcel Dekker, New York, 1993, 1–42.
20. Benson, H.A. Transdermal drug delivery: Penetration enhancement techniques. Curr Drug Deliv., 2(1), 2005, 23–33.
21. Prausnitz, M.R. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev., 56(5), 2004, 581–587.
22. Prausnitz, M.R.; Mitragotri, S.; Langer, R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov., 3(2), 2004, 115–124.
23. Ita, K. Transdermal drug delivery: Progress and challenges. J Drug Deliv Sci Technol., 24(3), 2014, 245–250.
24. Lee, C.H.; Yeo, S.; Kim, M.S.; Lee, J. Advances in transdermal drug delivery systems: Innovative strategies for improved efficacy. J Control Release., 267, 2017, 64–73.
25. Park, J.H.; Choi, S.O.; Seo, S.; Choy, Y.B. Smart transdermal patches for real-time monitoring and controlled drug delivery. Adv Drug Deliv Rev., 144, 2019, 25–38.
26. Choi, E.H.; Lee, S.H. Transdermal drug delivery and the skin barrier. Exp Dermatol., 24(3), 2015, 177–183.
27. Patel, D.B.; Patel, K.H.; Patel, B.N.; Mehta, F.A. Future of transdermal drug delivery systems in respiratory diseases. Drug Dev Ind Pharm., 47(5), 2021, 677–690.